IN THIS ISSUE
Viewpoint
Arthur Lazarus, MD, MBA
Much more research is needed to determine the full effect of drug benefit designs, says the author, an official at AstraZeneca. Quality must be the foremost concern.
Legislation & Regulation
John Carroll
CMS has implemented 10 pilot programs that may very well be viewed as a make-or-break test for disease management.
Ethics
Michael S. Victoroff, MD
Boutique medicine is dysfunctional, but probably not unethical — so long as the lucky patients understand that they're not necessarily paying for better care.
Tomorrow's Medicine
Thomas Morrow, MD
Traditional therapies predominate in wound care, but for those patients with chronic conditions, engineered skin may be a welcome relief from pain and infection.
News and Commentary